Figure 2From: Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer Kaplan–Meier curves of progression-free survival in cohorts 1 and 2. Back to article page